Tissium
Develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.
- biotechnology
- sustainable development goals
- dt and ls
- woman founder
- radar de l'innovation
- tech for business
- observatoire industrial tech
- observatoire deeptech
- surgery
- digital care
- biotech, medtech and e-health
- non-invasive medical devices and treatments
- advanced materials
- tech for medical professionals
- observatoire healthtech
- participations bpifrance
- biomedical
- tissue engineering
- chemical
- biodegradable
- biopolymers
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | €4.2m | Debt | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 40966 % | (10 %) | (2 %) | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (62034 %) | (54 %) | (108 %) | (290 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (56432 %) | (43 %) | (87 %) | (286 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Tissium is a startup operating in the medical technology sector, specifically in the development and production of biopolymers. These biopolymers are designed to repair and reconstruct tissue in the human body. The company's innovative technology is based on the storage and access of technical data, which is used to improve the functionality and effectiveness of their products.
Tissium's primary clients are healthcare providers, including hospitals and clinics, who use their products for surgical procedures. The company operates in the global healthcare market, which is continually growing due to the increasing demand for advanced medical solutions.
The business model of Tissium is based on the development, production, and sale of their biopolymers. They invest heavily in research and development to create innovative products that meet the needs of their clients. Once these products are developed, they are sold to healthcare providers. The company generates revenue from the sale of these products.
Tissium also uses technical storage and access for statistical purposes. This data is used to track the performance of their products and to make improvements where necessary. However, the company ensures that this data is used responsibly and cannot be used to identify individuals without a subpoena or voluntary compliance from an Internet Service Provider.
In summary, Tissium is a medical technology startup that develops and sells biopolymers for tissue repair and reconstruction. They use technical data to improve their products and operate in the global healthcare market, serving healthcare providers.
Keywords: Medical Technology, Biopolymers, Tissue Repair, Healthcare Providers, Global Healthcare Market, Research and Development, Product Sales, Revenue Generation, Technical Data, Responsible Data Use.